PL2982372T3 - Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych - Google Patents

Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych

Info

Publication number
PL2982372T3
PL2982372T3 PL15182562T PL15182562T PL2982372T3 PL 2982372 T3 PL2982372 T3 PL 2982372T3 PL 15182562 T PL15182562 T PL 15182562T PL 15182562 T PL15182562 T PL 15182562T PL 2982372 T3 PL2982372 T3 PL 2982372T3
Authority
PL
Poland
Prior art keywords
treatment
mental disorders
modulating agents
glutamate modulating
glutamate
Prior art date
Application number
PL15182562T
Other languages
English (en)
Inventor
Vladmir Coric
John H. Krystal
Gerard Sanacora
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of PL2982372T3 publication Critical patent/PL2982372T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/10—Optical coatings produced by application to, or surface treatment of, optical elements
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/281—Interference filters designed for the infrared light
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/283—Interference filters designed for the ultraviolet
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/20—Filters
    • G02B5/28—Interference filters
    • G02B5/285—Interference filters comprising deposited thin solid films
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F39/00—Integrated devices, or assemblies of multiple devices, comprising at least one element covered by group H10F30/00, e.g. radiation detectors comprising photodiode arrays
    • H10F39/011—Manufacture or treatment of image sensors covered by group H10F39/12
    • H10F39/024—Manufacture or treatment of image sensors covered by group H10F39/12 of coatings or optical elements
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F39/00—Integrated devices, or assemblies of multiple devices, comprising at least one element covered by group H10F30/00, e.g. radiation detectors comprising photodiode arrays
    • H10F39/80—Constructional details of image sensors
    • H10F39/805—Coatings
    • H10F39/8053—Colour filters

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15182562T 2005-04-05 2006-04-05 Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych PL2982372T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US66873505P 2005-04-05 2005-04-05
US66977405P 2005-04-07 2005-04-07
US69018705P 2005-06-13 2005-06-13
US69462105P 2005-06-27 2005-06-27
US75647206P 2006-01-04 2006-01-04
EP10156331.0A EP2201963B1 (en) 2005-04-05 2006-04-05 Glutamate modulating agents in the treatment of mental disorders
PCT/US2006/012701 WO2006108055A1 (en) 2005-04-05 2006-04-05 Glutamate modulating agents in the treatment of mental disorders
EP15182562.7A EP2982372B1 (en) 2005-04-05 2006-04-05 Glutamate modulating agents in the treatment of mental disorders
EP06749354A EP1874353A1 (en) 2005-04-05 2006-04-05 Glutamate modulating agents in the treatment of mental disorders

Publications (1)

Publication Number Publication Date
PL2982372T3 true PL2982372T3 (pl) 2020-12-28

Family

ID=36659964

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15182562T PL2982372T3 (pl) 2005-04-05 2006-04-05 Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych

Country Status (11)

Country Link
US (7) US8778979B2 (pl)
EP (4) EP2982372B1 (pl)
CY (1) CY1124111T1 (pl)
DK (1) DK2201963T3 (pl)
ES (2) ES2819303T3 (pl)
HU (1) HUE050758T2 (pl)
LT (1) LT2982372T (pl)
PL (1) PL2982372T3 (pl)
PT (1) PT2982372T (pl)
SI (1) SI2982372T1 (pl)
WO (1) WO2006108055A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186219B2 (ja) * 2005-01-25 2013-04-17 エピックス デラウェア， インコーポレイテッド 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US20100099762A1 (en) * 2006-10-23 2010-04-22 The Mental Health Research Institute Of Victoria Combination therapy
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8173809B2 (en) * 2008-02-07 2012-05-08 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
ES2530047T3 (es) 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
US9433596B2 (en) * 2010-09-06 2016-09-06 Snu R&Db Foundation Pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder
US20120270860A1 (en) * 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
DK3265448T3 (da) 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
WO2016184911A1 (en) * 2015-05-18 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of the neuropathology of patients suffering from myotonic dystrophy type 1 (dm1)
CN112584831A (zh) * 2018-08-16 2021-03-30 拜奥海芬治疗学有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4584250A4 (en) * 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5310897A (en) 1984-12-27 1994-05-10 Sumitomo Pharmaceuticals Co., Ltd. Beta-lactams and their production
EP0241809B1 (de) 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
WO1991006291A1 (fr) 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Preparation a liberation entretenue
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5104761A (en) 1990-09-14 1992-04-14 Eastman Kodak Company Interdispersed three-phase ferrite composite and electrographic magnetic carrier particles therefrom
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6057373A (en) 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
CA2328411C (en) * 1998-05-15 2008-12-16 Alan F. Schatzberg Glucocorticoid receptor antagonists for the treatment of dementia
US6031094A (en) 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
WO2001012171A2 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US20030162694A1 (en) * 2002-02-04 2003-08-28 James Meyerhoff Novel treatment for pathological aggression
WO2004056335A2 (es) 2002-12-23 2004-07-08 Osmotica Costa Rica Sociedad Anonima Dispositivo de liberación que contiene venlafaxina y memantina
EP1611238B1 (en) 2003-02-26 2009-06-17 The John Hopkins University Glutamate transport modulatory compounds and methods
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US20060167068A1 (en) 2005-01-26 2006-07-27 Seth Feuerstein Method of treating self-injurious behavior with glutamate modulating agents
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
KR100748513B1 (ko) 2005-10-07 2007-08-14 엘지전자 주식회사 위치 서비스 방법 및 시스템
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires

Also Published As

Publication number Publication date
LT2982372T (lt) 2020-10-26
EP2982372A1 (en) 2016-02-10
EP3753561A1 (en) 2020-12-23
US20140249173A1 (en) 2014-09-04
CY1124111T1 (el) 2022-03-24
HUE050758T2 (hu) 2021-01-28
US20060270647A1 (en) 2006-11-30
WO2006108055A1 (en) 2006-10-12
EP1874353A1 (en) 2008-01-09
US20170360775A1 (en) 2017-12-21
US8778979B2 (en) 2014-07-15
US20210093630A1 (en) 2021-04-01
US11554117B2 (en) 2023-01-17
DK2201963T3 (en) 2016-02-15
US20210093629A1 (en) 2021-04-01
EP2201963B1 (en) 2016-01-27
US10052318B2 (en) 2018-08-21
ES2819303T3 (es) 2021-04-15
US20210294011A1 (en) 2021-09-23
US20180318288A1 (en) 2018-11-08
SI2982372T1 (sl) 2020-11-30
PT2982372T (pt) 2020-10-09
EP2201963A1 (en) 2010-06-30
ES2564187T3 (es) 2016-03-18
EP2982372B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
IL184363A0 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HRP20130353T1 (hr) Sredstva za prevenciju i lijeäśenje poremeä†aja koji obuhvaä†aju modulaciju ryr receptora
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
ZA200900055B (en) Modulators of metabolism and the treatment of disorders related thereto
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
IL188922A0 (en) Benzoquinazoline derivatives and their use in treating bone disorders
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
SI2982372T1 (sl) Sredstva za modulacijo glutamata pri zdravljenju mentalnih motenj
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
EP1942911A4 (en) THERAPEUTIC MOLECULES AND USES THEREOF
HK1116674A (en) Glutamate modulating agents in the treatment of mental disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
ZA200800409B (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
PL2066314T3 (pl) Zastosowanie teogaliny do leczenia umysłowych zaburzeń zdolności do koncentracji, depresji i demencji
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders